Josh Phillipson 9/11/23 Josh Phillipson 9/11/23

Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston

Read More

Josh Phillipson 9/6/23 Josh Phillipson 9/6/23

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics

Scinai Immunotherapeutics

Read More

Amir Reichman 8/11/23 Amir Reichman 8/11/23

BiondVax Reports Second Quarter Financial Results and Provides Business Update

Read More

Amir Reichman 8/1/23 Amir Reichman 8/1/23

Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules

Read More

Amir Reichman 6/5/23 Amir Reichman 6/5/23

BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis

Read More

Amir Reichman 5/15/23 Amir Reichman 5/15/23

BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update

Read More

Amir Reichman 4/17/23 Amir Reichman 4/17/23

BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update

Read More

Amir Reichman 3/16/23 Amir Reichman 3/16/23

BiondVax to Present at BIO-Europe Spring

Read More

Amir Reichman 2/2/23 Amir Reichman 2/2/23

BiondVax Presenting at BIO CEO & Investor Conference

Read More

Amir Reichman 1/23/23 Amir Reichman 1/23/23

BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study

Read More

Amir Reichman 1/6/23 Amir Reichman 1/6/23

BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study

Read More

Amir Reichman 1/5/23 Amir Reichman 1/5/23

BiondVax to Present at Biotech Showcase 2023

Read More